ON-ICE trial: Investigation of the combined effects of oxytocin and naltrexone on stress-induced and alcohol cue-induced craving in alcohol use disorder-Study protocol of a phase II randomised double-blind placebo-controlled parallel-group trial

Sina Zimmermann, Bettina C Thomas, Johannes Krisam, Ronald Limprecht, Christina Klose, Manuel Stenger, Madeleine Pourbaix, Marcel Ries, Sabine Vollstaedt-Klein, Anne Koopmann, Bernd Lenz, Falk Kiefer, Patrick Bach, Sina Zimmermann, Bettina C Thomas, Johannes Krisam, Ronald Limprecht, Christina Klose, Manuel Stenger, Madeleine Pourbaix, Marcel Ries, Sabine Vollstaedt-Klein, Anne Koopmann, Bernd Lenz, Falk Kiefer, Patrick Bach

Abstract

Introduction: Although alcohol dependence (AD) is highly prevalent, only few medications are approved for its treatment. While currently approved medications, such as naltrexone (NTX), reduce craving and relapse risk to a certain extent, new approaches are needed to complement these pharmaca. One potential compound is oxytocin (OXY), which proved beneficial effects on alcohol craving and stress reactivity in preliminary clinical studies and synergism with NTX effects.

Methods and analysis: This clinical phase II trial is a monocentre two-armed, placebo (PLC)-controlled, 1:1 randomised, double-blind, parallel-group study. 62 participants with AD will be randomised to receive either intranasal OXY spray (24 IU) or PLC spray plus oral NTX (50 mg) for 2 days, and alcohol craving will be assessed using a validated combined stress-exposure and cue-exposure experiments and MRI. The primary outcome will be the intensity of alcohol craving, assessed using the Alcohol Urge Questionnaire (AUQ), 60 min after OXY/PLC application, directly after the stress and cue exposures. Secondary outcomes include subjective stress, negative affect, cortisol and OXY plasma levels, and neural response to alcohol and emotional cues and natural rewards. Follow-up drinking data were collected over 90 days. The primary efficacy analysis will test the difference between the verum and the PLC group in the distribution of AUQ craving scores. Appropriate statistical analysis will be used for the evaluation of the secondary outcomes.

Ethics and dissemination: This trial has been approved by the ethics committee of Heidelberg University and competent authority. All participants in the trial will provide written informed consent. The study will be conducted according to the principles of the Declaration of Helsinki and in accordance to the German Medicinal Products act. Results of this study will be disseminated in peer-reviewed scientific journals and deidentified data, and the statistical analysis plan will be made available via open-access online repositories.

Trial registration numbers: EudraCT 2021-003610-40 and NCT05093296.

Keywords: Clinical trials; MENTAL HEALTH; Pharmacology; RADIOLOGY & IMAGING; Substance misuse.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Clinical trial design.

References

    1. Rösner S, Hackl-Herrwerth A, Leucht S, et al. . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010;5. 10.1002/14651858.CD001867.pub3
    1. Brownell KD, Marlatt GA, Lichtenstein E, et al. . Understanding and preventing relapse. Am Psychol 1986;41:765–82. 10.1037/0003-066X.41.7.765
    1. Pedersen CA, Smedley KL, Leserman J, et al. . Intranasal oxytocin blocks alcohol withdrawal in human subjects. Alcohol Clin Exp Res 2013;37:484–9. 10.1111/j.1530-0277.2012.01958.x
    1. McRae-Clark AL, Baker NL, Maria MM-S, et al. . Effect of oxytocin on craving and stress response in marijuana-dependent individuals: a pilot study. Psychopharmacology 2013;228:623–31. 10.1007/s00213-013-3062-4
    1. Hansson AC, Koopmann A, Uhrig S, et al. . Oxytocin reduces alcohol Cue-Reactivity in alcohol-dependent rats and humans. Neuropsychopharmacology 2018;43:1235–46. 10.1038/npp.2017.257
    1. Bach P, Vollstädt-Klein S, Kirsch M, et al. . Increased mesolimbic cue-reactivity in carriers of the mu-opioid-receptor gene OPRM1 A118G polymorphism predicts drinking outcome: a functional imaging study in alcohol dependent subjects. Eur Neuropsychopharmacol 2015;25:1128–35. 10.1016/j.euroneuro.2015.04.013
    1. Sinha R, Fox HC, Hong K-IA, et al. . Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes. Arch Gen Psychiatry 2011;68:942–52. 10.1001/archgenpsychiatry.2011.49
    1. Bicknell RJ, Leng G. Endogenous opiates regulate oxytocin but not vasopressin secretion from the neurohypophysis. Nature 1982;298:161–2. 10.1038/298161a0
    1. Peters ST, Bowen MT, Bohrer K, et al. . Oxytocin inhibits ethanol consumption and ethanol-induced dopamine release in the nucleus accumbens. Addict Biol 2017;22:702–11. 10.1111/adb.12362
    1. Dal Monte O, Piva M, Anderson KM, et al. . Oxytocin under opioid antagonism leads to supralinear enhancement of social attention. Proc Natl Acad Sci U S A 2017;114:5247–52. 10.1073/pnas.1702725114
    1. King CE, Griffin WC, Luderman LN, et al. . Oxytocin reduces ethanol self-administration in mice. Alcohol Clin Exp Res 2017;41:955–64. 10.1111/acer.13359
    1. Stevenson JR, Wenner SM, Freestone DM, et al. . Oxytocin reduces alcohol consumption in prairie voles. Physiol Behav 2017;179:411–21. 10.1016/j.physbeh.2017.07.021
    1. Mitchell JM, Arcuni PA, Weinstein D, et al. . Intranasal oxytocin selectively modulates social perception, craving, and approach behavior in subjects with alcohol use disorder. J Addict Med 2016;10:182–9. 10.1097/ADM.0000000000000213
    1. Spengler FB, Schultz J, Scheele D, et al. . Kinetics and dose dependency of intranasal oxytocin effects on amygdala reactivity. Biol Psychiatry 2017;82:885–94. 10.1016/j.biopsych.2017.04.015
    1. Striepens N, Kendrick KM, Hanking V, et al. . Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans. Sci Rep 2013;3:3440. 10.1038/srep03440
    1. Grace SA, Rossell SL, Heinrichs M, et al. . Oxytocin and brain activity in humans: a systematic review and coordinate-based meta-analysis of functional MRI studies. Psychoneuroendocrinology 2018;96:6–24. 10.1016/j.psyneuen.2018.05.031
    1. Chan A-W, Tetzlaff JM, Altman DG, et al. . Spirit 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200–7. 10.7326/0003-4819-158-3-201302050-00583
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Moher D, Hopewell S, Schulz KF, et al. . Consort 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010;63:e1–37. 10.1016/j.jclinepi.2010.03.004
    1. Kwako LE, Schwandt ML, Sells JR, et al. . Methods for inducing alcohol craving in individuals with co-morbid alcohol dependence and posttraumatic stress disorder: behavioral and physiological outcomes. Addict Biol 2015;20:733–46. 10.1111/adb.12150
    1. Bach P, Weil G, Pompili E, et al. . Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. Addict Biol 2020;25:e12717. 10.1111/adb.12717
    1. Kiefer F, Jahn H, Tarnaske T, et al. . Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003;60:92–9. 10.1001/archpsyc.60.1.92
    1. Kiefer F, Kirsch M, Bach P, et al. . Effects of D-cycloserine on extinction of mesolimbic cue reactivity in alcoholism: a randomized placebo-controlled trial. Psychopharmacology 2015;232:2353–62. 10.1007/s00213-015-3882-5
    1. Vollstädt-Klein S, Loeber S, Richter A, et al. . Validating incentive salience with functional magnetic resonance imaging: association between mesolimbic cue reactivity and attentional bias in alcohol-dependent patients. Addict Biol 2012;17:807–16. 10.1111/j.1369-1600.2011.00352.x
    1. Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993;28:76–81. 10.1159/000119004
    1. Bohn MJ, Krahn DD, Staehler BA. Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 1995;19:600–6. 10.1111/j.1530-0277.1995.tb01554.x
    1. Sinha R. Modeling relapse situations in the human laboratory. Behavioral neurobiology of alcohol addiction: Springer, 2011: 379–402.
    1. Hariri AR, Tessitore A, Mattay VS, et al. . The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 2002;17:317–23. 10.1006/nimg.2002.1179
    1. Gan G, Guevara A, Marxen M, et al. . Alcohol-Induced impairment of inhibitory control is linked to attenuated brain responses in right fronto-temporal cortex. Biol Psychiatry 2014;76:698–707. 10.1016/j.biopsych.2013.12.017
    1. Miller WR. Form 90: a structured assessment interview for drinking and related behaviors: test manual 1996.
    1. Zhao YD, Rahardja D, Qu Y. Sample size calculation for the Wilcoxon-Mann-Whitney test adjusting for ties. Stat Med 2008;27:462–8. 10.1002/sim.2912
    1. Brunner E, Munzel U. The nonparametric Behrens-Fisher problem: asymptotic theory and a Small-Sample approximation. Biometrical Journal 2000;42:17–25. 10.1002/(SICI)1521-4036(200001)42:1<17::AID-BIMJ17>;2-U
    1. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res 2007;16:219–42. 10.1177/0962280206074463
    1. Brunner E, Domhof S, Langer F. Nonparametric analysis of longitudinal data in factorial experiments: J. New York: Wiley, 2002.
    1. Hautzinger MK, Kühner F, Beck AT. Beck Depressions-Inventar : BDI II. Frankfurt am Main: Frankfurt am Main: Pearson Assessment, 2009.
    1. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988;54:1063–70. 10.1037/0022-3514.54.6.1063
    1. Gaab J. PASA – primary appraisal secondary appraisal. Verhaltenstherapie 2009;19:114–5. 10.1159/000223610
    1. World Health Organization . WHOQOL-BREF : introduction, administration, scoring and generic version of the assessment : field trial version. In: Division of mental H. Geneva: World Health Organization, 1996.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere